MAPK8 and glioma: Notably, ZDHHC17-promoted activation of JNK/p38 was PAT-independent, and ZDHHC17-expressing glioma cell malignancy characteristics were not suppressed by the PAT inhibitor, 2-bromopalmitate (2BP).